Loading...
Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
07 Dec 25
Views
151
07 Dec
US$4.40
AnalystConsensusTarget's Fair Value
US$8.50
48.2% undervalued intrinsic discount1Y
221.2%7D
3.0%1Y
221.2%7D
3.0%You can edit this narrative until Dec 8 6:05 AM. Then, changes will post as Updates.
Author's Valuation
US$8.548.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value